Jiangsu Lanxinping Pharmaceutical

Jiangsu Lanxinping Pharmaceutical is a clinical-stage biopharmaceutical company based in China, focused on the discovery and development of innovative small molecule therapeutics for oncology and other unmet medical needs. The company leverages its internal R&D capabilities to target well-validated pathways such as FGFR and KRAS, aiming to provide more effective treatment options for cancer patients. Its lead programs include highly selective inhibitors designed to overcome resistance mechanisms in solid tumors. Lanxinping is part of the growing ecosystem of innovative biotech firms in the Jiangsu province, emphasizing precision medicine and targeted therapy.